Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some conventional chemotherapeutic drugs depend on the activation of p53 for their efficacy.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Comparing p53-proficient and -deficient HCT116 cells, such a dependency was found in particular for 5-fluorouracil (5-FU)44.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“On the other hand, the same report showed that p53-deficient cells displayed a higher sensitivity towards topoisomerase inhibitors such as Adriamycin.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 4×
“We attribute this difference to the small amount of p53independent p21 induction following DNA damage that occurs after adriamycin treatment of p53-deficient cells (not shown), similar to that observed after γ-irradiation (14).”
BackgroundMethodInfluentialSelf-citationA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“Introduction The p53 gene is inactivated in the majority of human cancers, resulting in profound effects on cell birth and death processes (1, 2).”
BackgroundMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469 · cited 1×
“with mouse cells, for example, have provided unequivocal evidence of drug resistance after p53 inactivation (9, 10), but the extrapolation of these results to humans is far from straightforward.”
BackgroundApoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · cited 1×
“The checkpoint function of p53 is mediated by the genes it transcriptionally regulates, including p21 (14, 15, 16) and 14-3-3σ (28), and keeps cells from progressing from G1 to S or G2 to M after DNA damage.”
BackgroundSelf-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
Research works printed but not linked: 6
- Hawkins, 1996, Cancer Res, 56, 892
- O’Connor, 1997, Cancer Res, 57, 4285
- Waldman, 1995, Cancer Res, 55, 5187
- Geoffroy, 1994, Oncol Res, 6, 581
- Wyllie, 1997, Eur J Cell Biol, 73, 189
- Cory, 1979, Cancer Res, 39, 4905
Cited by
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
“In vitro studies have reported that loss of p53 function reduces cellular sensitivity to 5-F”
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Death and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Lowe, S. W., & Lin, A. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.485 · Cited by 1,876
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
“For example, in vitro studies have reported that loss of p53 function reduces chemosensitivity to 5-FU [49,121].”
BackgroundPUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells
Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., & Vogelstein, B. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00213-1 · Cited by 1,280
Self-citationRegulation of autophagy by cytoplasmic p53
Tasdemir, E., Maiuri, M. C., Galluzzi, L., Vitale, I., Djavaheri-Mergny, M., D'Amelio, M., Criollo, A., Morselli, E., Zhu, C., Harper, F., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1730 · Cited by 1,132
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
“In vitro studies have reported that loss of p53 function reduces apoptosis by 5-FU [57].”
BackgroundRetractedRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
“In contrast, 5-FU inhibited growth more efficiently in tumor cells carrying wild-type p53 (ref”
BackgroundDecision making by p53: life, death and cancer
Oren, M. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,068
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
The role of apoptosis in cancer development and treatment response
Brown, J. M., & Attardi, L. D. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1560 · Cited by 944
The role of the cyclin-dependent kinase inhibitor p21 in apoptosis.
Gartel, A. L., & Tyner, A. L. (2002) · PubMed · Cited by 1,075
Tazawa, H., Tsuchiya, N., Izumiya, M., & Nakagama, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707351104 · Cited by 903
Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon Cancer
Watanabe, T., Wu, T.-T., Catalano, P. J., Ueki, T., Satriano, R., Haller, D. G., Benson, A. B., & Hamilton, S. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104193441603 · Cited by 888
Role of BAX in the Apoptotic Response to Anticancer Agents
Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., & Vogelstein, B. (2000) · Science · doi:10.1126/science.290.5493.989 · Cited by 863
Self-citationTakaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847
“5-Fluorouracil (5-FU) is one agent whose efficacy closely correlates with the p53 status of cancer cell”
BackgroundApoptosis and melanoma chemoresistance
Soengas, M. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206454 · Cited by 826
“One explanation for this paradox is that p53 does not influence treatment responses in this tumor type or, indeed, loss of p53 actually increases drug sensitivity as has been observed in some experimental contexts (Bunz et al., 1999).”
BackgroundSmall molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
Regulation of p53 Translation and Induction after DNA Damage by Ribosomal Protein L26 and Nucleolin
Takagi, M., Absalon, M. J., McLure, K. G., & Kastan, M. B. (2005) · Cell · doi:10.1016/j.cell.2005.07.034 · Cited by 663
“Transfection of RPL26 also increased 5-fluorouracil-dependent cell death in human HCT116 colon cancer cells carrying wild-type p53 (Bunz et al., 1999) but had no measurable effect in isogenic HCT116 cells lacking p53 (Figure 6C).”
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 654
Morselli, E., Maiuri, M. C., Markaki, M., Megalou, E., Pasparaki, A., Palikaras, K., Criollo, A., Galluzzi, L., Malik, S. A., Vitale, I., et al. (2010) · Cell Death & Disease · doi:10.1038/cddis.2009.8 · Cited by 613
The molecular biology of cancer
Bertram, J. S. (2000) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(00)00007-8 · Cited by 585
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 587
The role of p53 in determining sensitivity to radiotherapy
Gudkov, A. V., & Komarova, E. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc992 · Cited by 572
“Otherwise, they can overshadow the positive role of p53 in DNA repair, and p53 deficiency in these cases would be associated with increased radioresistanc”
BackgroundApoptosis defects and chemotherapy resistance: molecular interaction maps and networks
Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., & Kohn, K. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207515 · Cited by 560
“For example, two competing p53-mediated responses to cytotoxics can be observed in vitro, namely cell death or cell cycle arrest (Waldman et al., 1997; elDeiry, 1998; Bunz et al., 1999).”
BackgroundMutational processes shape the landscape of TP53 mutations in human cancer
Giacomelli, A. O., Yang, X., Lintner, R. E., McFarland, J. M., Duby, M., Kim, J., Howard, T. P., Takeda, D. Y., Ly, S. H., Kim, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0204-y · Cited by 556
Yemelyanova, A., Vang, R., Kshirsagar, M., Lu, D., Marks, M. A., Shih, I. M., & Kurman, R. J. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.85 · Cited by 513
“For example, the presence of a TP53 mutation in colorectal, lung, prostate, and breast carcinomas has been shown to be a poor prognostic factor, and for the tumors of other sites a TP53 mutation has been associated with chemoresistance in some studies”
BackgroundSpermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome
Morselli, E., Mariño, G., Bennetzen, M. V., Eisenberg, T., Megalou, E., Schroeder, S., Cabrera, S., Bénit, P., Rustin, P., Criollo, A., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201008167 · Cited by 499
“Institute, Johns Hopkins University, Baltimore, MD; Bunz et al., 1999) were cultured in McCoy’s 5A medium containing 10% fetal bovine serum, 100 mg/liter sodium pyruvate, 10-mM Hepes buffer, 100 U/ml penicillin G sodium, and 100 µg/ml streptomycin sulfate (5% CO2 at 37°C).”
MethodCell cycle checkpoint signaling:
Pietenpol, J. A., & Stewart, Z. A. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00460-2 · Cited by 473
p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest
Braun, C. J., Zhang, X., Savelyeva, I., Wolff, S., Moll, U. M., Schepeler, T., Ørntoft, T. F., Andersen, C. L., & Dobbelstein, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1569 · Cited by 473
Chromosome segregation and cancer: cutting through the mystery
Jallepalli, P. V., & Lengauer, C. (2001) · Nature Reviews Cancer · doi:10.1038/35101065 · Cited by 463
“The p53 DNA-damage checkpoint has implications for cancer therapy, as p53-deficient cells undergo inappropriate mitosis in the presence of ionizing radiation and other clinically important DNA-damaging agents, resulting in their preferential demis”
BackgroundSelf-citationINK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Genes & Development · doi:10.1101/gad.13.20.2670 · Cited by 458
“As for p53 mutations, it seems likely that the overall impact of INK4a/ARF disruption on chemoresistance will depend on additional factors, such as tissue type, agent, and the mutational background of the tumor (for review, see Wallace-Brodeur and Lowe 1999; also see Bunz et al. 1999).”
BackgroundIdentification and classification of p53-regulated genes
Yu, J., Zhang, L., Hwang, P. M., Rago, C., Kinzler, K. W., & Vogelstein, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14517 · Cited by 452
Self-citationChemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels
Burger, K., Mühl, B., Harasim, T., Rohrmoser, M., Malamoussi, A., Orban, M., Kellner, M., Gruber-Eber, A., Kremmer, E., Hölzel, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.074211 · Cited by 458
Cancer Chemotherapy and Pharmacology
(2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/280.1432-0843 · Cited by 430
Hwang, P. M., Bunz, F., Yu, J., Rago, C., Chan, T. A., Murphy, M. P., Kelso, G. F., Smith, R. A. J., Kinzler, K. W., & Vogelstein, B. (2001) · Nature Medicine · doi:10.1038/nm1001-1111 · Cited by 422
Self-citationMultiple Tumor Suppressor Pathways Negatively Regulate Telomerase
Lin, S.-Y., & Elledge, S. J. (2003) · Cell · doi:10.1016/s0092-8674(03)00430-6 · Cited by 363
The transcriptional targets of p53 in apoptosis control
Yu, J., & Zhang, L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.189 · Cited by 420
BID regulation by p53 contributes to chemosensitivity
Sax, J. K., Fei, P., Murphy, M. E., Bernhard, E., Korsmeyer, S. J., & El-Deiry, W. S. (2002) · Nature Cell Biology · doi:10.1038/ncb866 · Cited by 420
“Cells with a disrupted p53 gene are resistant to the effects of 5-F”
BackgroundRusso, A., Bazan, V., Iacopetta, B., Kerr, D., Soussi, T., & Gebbia, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.471 · Cited by 416
“However, in vitro studies have shown that disruption of TP53 causes colorectal cancer cells to be more resistant to the apoptotic effects of FU.(52) In agreement with these observations, we found that colorectal cancer patients with wild-type TP53 have significantly better survival when treated with chemotherapy compa…”
ResultMolecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 407
“mutation of p53 can render cells or tumors more sensitive to treatment [21,22].”
BackgroundMechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells
Song, B., Wang, Y., Xi, Y., Kudo, K., Bruheim, S., Botchkina, G. I., Gavin, E., Wan, Y., Formentini, A., Kornmann, M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.274 · Cited by 410
“This was consistent with a previous report that p21 induction was associated with 5-FU resistance (Bunz et al., 1999).”
ResultThe genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis
Chung, D. C. (2000) · Gastroenterology · doi:10.1053/gast.2000.16507 · Cited by 414
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Hu, T., Li, Z., Gao, C.-Y., & Cho, C. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6876 · Cited by 381
Disruption of HAUSP gene stabilizes p53.
Cummins, J. M., Rago, C., Kohli, M., Kinzler, K. W., Lengauer, C., & Vogelstein, B. (2004) · Nature · doi:10.1038/nature02501 · Cited by 379
Self-citationJaiswal, A. S., Marlow, B. P., Gupta, N., & Narayan, S. (2002) · Oncogene · doi:10.1038/sj.onc.1205947 · Cited by 363
“Two isogenic clones were derived from the HCT116(p53+/+) cell line by targeted deletion of p53 and p21 genes (Bunz et al., 1999).”
Methodp53 Suppresses the Nrf2-dependent Transcription of Antioxidant Response Genes
Faraonio, R., Vergara, P., Di Marzo, D., Pierantoni, M. G., Napolitano, M., Russo, T., & Cimino, F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605707200 · Cited by 349
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL
Tzoneva, G., Perez-Garcia, A., Carpenter, Z., Khiabanian, H., Tosello, V., Allegretta, M., Paietta, E., Racevskis, J., Rowe, J. M., Tallman, M. S., et al. (2013) · Nature Medicine · doi:10.1038/nm.3078 · Cited by 350
TP53 mutation in colorectal cancer
Iacopetta, B. (2003) · Human Mutation · doi:10.1002/humu.10175 · Cited by 345
“These clinical results are in agreement with in vitro and animal studies that show a requirement for normal p53 in order for colorectal tumor cells to respond to 5FU [Bunz et al., 1999].”
ResultAllen, J. E., Krigsfeld, G., Mayes, P. A., Patel, L., Dicker, D. T., Patel, A. S., Dolloff, N. G., Messaris, E., Scata, K. A., Wang, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004828 · Cited by 342
The Role of p53 Signaling in Colorectal Cancer
Liebl, M. C., & Hofmann, T. G. (2021) · Cancers · doi:10.3390/cancers13092125 · Cited by 318
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
“These data in breast cancer cell lines are similar to observations in other cell lines, such as the isogenic variants of the HCT-116 colon cancer cell line that lack p53 or p21 (Bunz et al., 1999;Waldman et al., 1997).”
Genetic profile of 22 pancreatic carcinoma cell lines: Analysis of K-ras, p53, p16 and DPC4/Smad4
Moore, P. S., Sipos, B., Orlandini, S., Sorio, C., Real, F. X., Lemoine, N. R., Gress, T., Bassi, C., Klöppel, G., Kalthoff, H., et al. (2001) · Virchows Archiv · doi:10.1007/s004280100474 · Cited by 329
Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells
Colland, F., Formstecher, E., Jacq, X., Reverdy, C., Planquette, C., Conrath, S., Trouplin, V., Bianchi, J., Aushev, V. N., Camonis, J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0097 · Cited by 321
“We then investigated the proapoptotic effect of HBX 41,108 on HCT116 cell lines in which the p53 pathway was specifically disrupted by targeted homologous recombination (29).”
BackgroundAssociation of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 319
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Kaeser, M. D., & Iggo, R. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012283399 · Cited by 302
Repression of the miR‐17‐92 cluster by p53 has an important function in hypoxia‐induced apoptosis
Yan, H., Xue, G., Mei, Q., Wang, Y., Ding, F., Liu, M., Lu, M., Tang, Y., Yu, H., & Sun, S. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.214 · Cited by 300
“To exclude a possible effect of cellular background, we compared the expression of miR-17-92 in hypoxia-treated isogenic HCT116 p53þ /þ and HCT116 p53 / cell lines (Bunz et al, 1999).”
MethodCancer-Specific Functions of SIRT1 Enable Human Epithelial Cancer Cell Growth and Survival
Ford, J., Jiang, M., & Milner, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1923 · Cited by 298
“generated by the Vogelstein Laboratory with gene knockouts for p53, Bax, and p21 (25, 26).”
BackgroundMethodP53 abnormalities and outcomes in colorectal cancer: a systematic review
Munro, A. J., Lain, S., & Lane, D. P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602358 · Cited by 289
“…of p53, and its abnormalities, on the response of tumours to cytotoxic drugs, radiation, and chemoradiation are complex (Blandino et al, 1999; Bunz et al, 1999; ElDeiry, 2003; Fei and El-Deiry, 2003; Gudkov and Komarova, 2003), and it is, perhaps, unrealistic to expect a straightforward…”
BackgroundA Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Bernal, F., Wade, M., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 285
“Genetic deletion of p53 from HCT116 cells (Bunz et al., 1999) or overexpression of a dominant-negative form of p53 in SJSA-1 cells (Shaulian et al.”
InfluentialAllegra, C. J., Paik, S., Colangelo, L. H., Parr, A. L., Kirsch, I., Kim, G., Klein, P., Johnston, P. G., Wolmark, N., & Wieand, H. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.044 · Cited by 282
A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization
Aylon, Y., Michael, D., Shmueli, A., Yabuta, N., Nojima, H., & Oren, M. (2006) · Genes & Development · doi:10.1101/gad.1447006 · Cited by 284
“Essentially identical results were obtained with p53positive HCT116 colorectal cancer cells and their derivatives in which the p53 gene had been somatically knocked out (Bunz et al. 1999).”
Accelerated senescence: An emerging role in tumor cell response to chemotherapy and radiation
Gewirtz, D. A., Holt, S. E., & Elmore, L. W. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.06.024 · Cited by 281
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
Baig, S., Seevasant, I., Mohamad, J., Mukheem, A., Huri, H. Z., & Kamarul, T. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.275 · Cited by 279
Mutant p53 protein localized in the cytoplasm inhibits autophagy
Morselli, E., Tasdemir, E., Chiara Maiuri, M., Galluzzi, L., Kepp, O., Criollo, A., Vicencio, J. M., Soussi, T., & Kroemer, G. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6751 · Cited by 277
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
Arango, D., Wilson, A. J., Shi, Q., Corner, G. A., Arañes, M. J., Nicholas, C., Lesser, M., Mariadason, J. M., & Augenlicht, L. H. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602215 · Cited by 274
“The platinum compound oxaliplatin is frequently used in the treatment of colorectal cancer patients that are resistant to 5FU, and can also be used in combination with 5FU or CPT-11, improving response rates and progression-free survival (Levi et al, 1993; Bertheault-Cvitkovic et al, 1996; Machover et al, 1996; de Gra…”
BackgroundInfluentialPrognostic Values of microRNAs in Colorectal Cancer.
Xi, Y., Formentini, A., Chien, M., Weir, D. B., Russo, J. J., Ju, J., Kornmann, M., & Ju, J. (2006) · PubMed Central · Cited by 293
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance
Kaufmann, S. H., & Vaux, D. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206945 · Cited by 265
“Studies in tissue culture have indicated that p53 deletion can render both E1A/ras-transformed fibroblasts (Lowe et al., 1993) and HCT116 colon cancer cells (Bunz et al., 1999) resistant to the induction of apoptosis by various anticancer drugs in vitro.”
BackgroundRole of p21 in Apoptosis and Senescence of Human Colon Cancer Cells Treated with Camptothecin
Han, Z., Wei, W., Dunaway, S., Darnowski, J. W., Calabresi, P., Sedivy, J., Hendrickson, E. A., Balan, K. V., Pantazis, P., & Wyche, J. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112401200 · Cited by 262
Cooperative effects of genes controlling the G2/M checkpoint
Chan, T. A., Hwang, P. M., Hermeking, H., Kinzler, K. W., & Vogelstein, B. (2000) · Genes & Development · doi:10.1101/gad.14.13.1584 · Cited by 262
“Previous work has demonstrated that 5-FU activates a p53-dependent apoptotic program (Bunz et al. 1999).”
BackgroundSelf-citationLeonova, K. I., Brodsky, L., Lipchick, B., Pal, M., Novototskaya, L., Chenchik, A. A., Sen, G. C., Komarova, E. A., & Gudkov, A. V. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216922110 · Cited by 261
“The selective toxicity to p53-null cells differentiates 5-aza-dC from other DNA damaging agents, which generally are more toxic to p53-WT cells (21).”
BackgroundGali‐Muhtasib, H. U., Diab‐Assaf, M., Boltze, C., Al-Hmaira, J., Hartig, R., Roessner, A., & Schneider‐Stock, R. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.4.857 · Cited by 193
Göllner, S., Oellerich, T., Agrawal-Singh, S., Schenk, T., Klein, H.-U., Rohde, C., Pabst, C., Sauer, T., Lerdrup, M., Tavor, S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4247 · Cited by 257
“Instead, the FLT3 N676K mutation, as well as TP53 mutations—both known to affect drug sensitivity 24,25 —were identified in MV4-11R cells ( Supplementary Table 5 ).”
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
“Studies in cultured human tumor cells and various mouse tumor models have shown that inactivation of p53 reduces or abrogates the apoptotic response to chemotherapy (Bunz et al., 1999; Keshelava et al., 2001; Schmitt, 2003).”
BackgroundTargeting p53 for Novel Anticancer Therapy
Wang, Z., & Sun, Y. (2010) · Translational Oncology · doi:10.1593/tlo.09250 · Cited by 250
“[52] Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J,”
BackgroundQu, L., Huang, S., Baltzis, D., Rivas-Estilla, A.-M., Pluquet, O., Hatzoglou, M., Koumenis, C., Taya, Y., Yoshimura, A., & Koromilas, A. E. (2004) · Genes & Development · doi:10.1101/gad.1165804 · Cited by 245
“Because HCT116 p53+/+ cells are more susceptible than p53−/− cells to the killing effects of 5-fluorouracil (5-FU) treatment (Bunz et al. 1999), we reasoned that inhibition of p53 activation by ER stress should rescue the p53+/+ cells, but not the p53−/− cells from 5-FU-induced death.”
BackgroundInfluentialMitochondrial signaling in cell death via the Bcl-2 family
Leibowitz, B., & Yu, J. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.6.11392 · Cited by 247
Critical role for Daxx in regulating Mdm2
Tang, J., Qu, L.-K., Zhang, J., Wang, W., Michaelson, J. S., Degenhardt, Y. Y., El-Deiry, W. S., & Yang, X. (2006) · Nature Cell Biology · doi:10.1038/ncb1442 · Cited by 238
“U2OS cells were transfected with Flag-tagged full length Daxx, Daxx(347-740) (defective in Mdm2 binding), or Daxx(1-260) (defective in Hausp binding).”
MethodDe Angelis, P. M., Svendsrud, D. H., Kravik, K. L., & Stokke, T. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-20 · Cited by 233
“p53 is known to play a central role as a mediator of the DNA damage response/cell cycle arrest and in apoptosis induction [1,14,15].”
BackgroundIn Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide
Ji, Y., Majumder, S., Millard, M., Borra, R., Bi, T., Elnagar, A. Y., Neamati, N., Shekhtman, A., & Camarero, J. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405108p · Cited by 233
p21Waf1/Cip1 as a therapeutic target in breast and other cancers
Weiss, R. H. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00308-8 · Cited by 237
Activation of p53 in cervical carcinoma cells by small molecules
Hietanen, S., Lain, S., Krausz, E., Blattner, C., & Lane, D. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8501 · Cited by 230
Boyer, J., McLean, E. G., Aroori, S., Wilson, P., McCulla, A., Carey, P. D., Longley, D. B., & Johnston, P. G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0362 · Cited by 229
“Mutations in p53 are seen in 40–50% of CRCs, and several in vitro studies have reported that loss of functional p53 reduces cellular sensitivity to 5-FU (15, 16).”
BackgroundGiannakakou, P., Robey, R., Fojo, T., & Blagosklonny, M. V. (2001) · Oncogene · doi:10.1038/sj.onc.1204487 · Cited by 229
“The human colon cancer cell line HCT116, and two clones lacking p21 (p217/7), S4 and S14, generated from HCT116 cells (Waldman et al., 1995) as well as HCT116 cells lacking p53, HCT116 p537/7 (Bunz et al., 1998, 1999) were a gift from Dr B Vogelstein (John Hopkins University).”
MethodThe prodigiosins, proapoptotic drugs with anticancer properties
Pérez-Tomás, R., Montaner, B., Llagostera, E., & Soto-Cerrato, V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00496-9 · Cited by 222
p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study
Ahrendt, S. A., Hu, Y., Buta, M., McDermott, M. P., Benoit, N., Yang, S. C., Wu, L., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.961 · Cited by 222
Erdal, H., Berndtsson, M., Castro, J., Brunk, U., Shoshan, M. C., & Linder, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408592102 · Cited by 218
p53 in breast cancer subtypes and new insights into response to chemotherapy
Bertheau, P., Lehmann-Che, J., Varna, M., Dumay, A., Poirot, B., Porcher, R., Turpin, E., Plassa, L.-F., de Roquancourt, A., Bourstyn, E., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.07.005 · Cited by 215
“in cellular models [12].”
HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21
Wilson, A. J., Byun, D.-S., Nasser, S., Murray, L. B., Ayyanar, K., Arango, D., Figueroa, M., Melnick, A., Kao, G. D., Augenlicht, L. H., et al. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-02-0139 · Cited by 214
“HCT116 cells with and without deletion of both p21 alleles were kind gifts from Dr Bert Vogelstein (The Johns Hopkins Oncology Center, Baltimore, MD) (Bunz et al., 1999).”
MethodImpact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis
Gunther, E. J., Moody, S. E., Belka, G. K., Hahn, K. T., Innocent, N., Dugan, K. D., Cardiff, R. D., & Chodosh, L. A. (2003) · Genes & Development · doi:10.1101/gad.1051603 · Cited by 214
“Mutations in p53 have been purported to play a role in tumor resistance to a variety of antineoplastic strategies including cytotoxic chemotherapy, ionizing radiation, and antiangiogenic therapy (Lowe et al. 1993, 1994; Bunz et al. 1999; Johnstone et al. 2002; Yu et al. 2002).”
BackgroundViolette, S., Poulain, L., Dussaulx, E., Pepin, D., Faussat, A., Chambaz, J., Lacorte, J., Staedel, C., & Lesuffleur, T. (2002) · International Journal of Cancer · doi:10.1002/ijc.10146 · Cited by 213
Liu, P., Kumar, I. S., Brown, S., Kannappan, V, Tawari, P. E., Tang, J. Z., Jiang, W., Armesilla, A. L., Darling, J. L., & Wang, W. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.534 · Cited by 209
“Overexpression of p21Waf1 induces anticancer drug resistance (Bunz et al, 1999; Lazzarini et al, 2008).”
BackgroundXi, Y., Shalgi, R., Fodstad, O., Pilpel, Y., & Ju, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1853 · Cited by 212
“The HCT-116 (wt-p53) and HCT-116 (nullp53) cell lines were a gift from Dr. Bert Vogelstein (The Johns Hopkins University, Baltimore, MD) and were described in detail previously (15, 16 ).”
MethodMariadason, J. M., Arango, D., Shi, Q., Wilson, A. J., Corner, G. A., Nicholas, C., Aranes, M., LESSER, M. L., Schwartz, E. L., & Augenlicht, L. H. (2003) · PubMed · Cited by 223
Droller, M. J. (2000) · PubMed · Cited by 207
Jin, S., Tong, T., Fan, W., Fan, F., Antinore, M. J., Zhu, X., Mazzacurati, L., Li, X., Petrik, K. L., Rajasekaran, B., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1206034 · Cited by 207
“The tumor suppressor p53 gene has been implicated in the control of cell cycle checkpoint in response to genotoxic stress (Bunz et al., 1998, 1999; Kastan et al., 1991, 1992).”
BackgroundElsaleh, H., Powell, B. L., McCaul, K. A., Grieu, F., Grant, R., Joseph, D., & Iacopetta, B. J. (2001) · PubMed · Cited by 204
The GADD45 Inhibition of Cdc2 Kinase Correlates with GADD45-mediated Growth Suppression
Jin, S., Antinore, M. J., Lung, F.-D. T., Dong, X., Zhao, H., Fan, F., Colchagie, A. B., Blanck, P., Roller, P. P., Fornace, A. J., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000284200 · Cited by 202
Metadata
- Authors
- Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Georgetown University (US)
- Johns Hopkins University (US)
- Corresponding author
- Vogelstein, Bert
- Venue
- Journal of Clinical Investigation
- Published
- 1999-08-01
- Volume
- 104
- Issue
- 3
- Pages
- 263-269
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC408422
- OpenAlex
- W1982097971
- Cited by
- 1,044
- References
- 33
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 23 · 2021: 19 · 2020: 27 · 2019: 26 · 2018: 25 · 2017: 24 · 2016: 36 · 2015: 32 · 2014: 35 · 2013: 43 · 2012: 38
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute (CA 57345, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, p53 deficiency, chemoresistance, 5-fluorouracil, antimetabolite resistance, p21, cyclin-dependent kinase inhibitors, DNA-damaging agents, chemosensitization, colon cancer, colorectal cancer, RNA metabolism, drug response
- MeSH terms
- Animals, Antineoplastic Agents, Colonic Neoplasms, DNA Damage, Doxorubicin, Fluorouracil, Humans, Mice, Nude, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Gene Deletion, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p21, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.